Characteristics of Subcutaneous Injectable Products as Presented to Study Participants
| Existing 3-Month Product | 4-Month Product Concept | 6-Month Product Concept | |
|---|---|---|---|
| Amount of medroxyprogesterone acetate | 104 mg | 104 mg | 150 mg |
| Reinjection window | 4 weeks | 1 week | Not specified |
| Ability to self-inject | Yes | Yes | No |
| Return to fertility | Not described | Potentially shorter than existing 3-month | Not specified |
| Side effects | Not described | Potentially fewer than existing 3-month | Similar to existing 3-month |
| Regulatory approval/ state of evidence | Approved | Studies demonstrate effectiveness for 4-months | Effectiveness trial is ongoing |